Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag plus standard immunosuppressive therapy for newly diagnosed severe aplastic anaemia
ACTRN12619001042134Phase 2Active, not recruiting
- Sponsor
- Monash University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in aplastic anemia, sponsored by Monash University. Primary endpoints: Complete response rate at 6 months and Acquired clonal evolution at 6 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ACTRN12619001042134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001042134.